NCT00873756View on ClinicalTrials.gov

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

FOLFOX regimen

Intravenous repeating dose

DRUG

bevacizumab

Intravenous repeating dose

DRUG

dulanermin

Intravenous repeating dose

Trial Locations (7)

27599

Chapel Hill

60426

Harvey

80045

Aurora

80528

Fort Collins

87131

Albuquerque

90095

Los Angeles

94115

San Francisco

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY